

This advertisement has not loaded yet, but
your article continues below.



This section is [Partnership Content](#) supplied by [GlobeNewswire](#)



GlobeNewswire

Optimi Health Natural Psilocybin

SIGN UP

the economy, work, energy, investors and
finance Our newsletters will keep you posted
on the economy, work, energy, investors and

Manage Print
Subscription

Sections

Search

Share

Subscribe

Sign In

--Company utilizes green chemistry to stabilize natural product with higher yields



GlobeNewswire

Oct 05, 2021 • 7 hours ago • 4 minute read • [Join the conversation](#)

VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) — **Optimi Health Corp.** (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to advise of a recent patent filing pertaining to a breakthrough process that facilitates the extraction of the natural products Psilocybin and Psilocin from mushrooms at higher yields than previously possible.

STORY CONTINUES BELOW

The instability of Psilocybin and Psilocin has historically been a difficult problem to solve. Compared to the total alkaloid content believed to be in mushrooms, analytical chemistry studies have shown a 3-fold decrease in the total alkaloid content when the alkaloids are extracted from mushrooms that have been subjected to dehydration. Optimi has discovered a novel, high yielding extraction technique by combining multiple process steps that collectively increase the total yield of alkaloids retrieved from the mushrooms.



Many companies in the sector frequently use synthetic Psilocybin due to the instability of Psilocin which has been shown to degrade due to its phenolic hydroxy group. Optimi’s unique extraction technique not only increases overall alkaloid yield, but also protects the active alkaloids from degradation. Optimi Health Chief Scientific Officer, Justin Kirkland notes, “I find the compounds produced by these mushrooms as quite precious and am delighted to have developed a procedure that maintains their integrity.”

STORY CONTINUES BELOW

STORY CONTINUES BELOW

This innovative molecular protection process is believed to increase the bioavailability and permeability of the active components of the mushroom. In keeping with Optimi Health's commitment to sustainability and the environment, the proprietary process protected in the patent filing extensively utilizes green chemistry. Additionally, the process aids in lowering the cost of the final drug product for the patient as well as creating improved manufacturing efficiencies and improved safety characteristics related to farm operations.

Optimi Health CEO Bill Ciprick states, "Today's announcement reflects our determination to advance the innovation of all-natural mushroom science. We've achieved a singular achievement which will ultimately enable future patients the ability to select a superior, natural solution for their needs. The fact our process is both cost-effective and offers higher yields is, of course, a potentially significant commercial factor for us. We are looking forward to implementing these improved procedures as the construction of our mushroom farm facilities nears completion and are excited to continue to develop our inhouse IP portfolio to bring added value to our venture and ultimately to our shareholders."

STORY CONTINUES BELOW

On Behalf of the Board of Directors,

Bill Ciprick
Chief Executive Officer
Optimi Health Corp.

ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer's license under Canada's Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: <https://optimihealth.ca/>.

STORY CONTINUES BELOW

FOR FURTHER INFORMATION CONTACT:

Investor Relations

Email: investors@optimihealth.ca

Phone: +1 (778) 930-1321

Web: <https://optimihealth.ca/>

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements pertaining to the Company’s potential Nasdaq listing, the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

STORY CONTINUES BELOW

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Forward-Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are

expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.



Financial Post Top Stories

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

Email Address

Sign Up

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

TRENDING

1 Posthaste: Ontarians and other Canadians are moving to Atlantic Canada in numbers not seen since 1961

2 Toronto housing market at 'critical juncture' as plunging listings push high prices higher

➤ Howard Levitt: Recognizing a person's pronouns is not an 'accommodation' but a basic employer

3 Howard Levitt: recognizing a person's pronouns is not an accommodation, but a basic employer obligation

4 Opinion: Alberta pipelines are bad but foreign oil is fine?

5 FP Explains: The right time to start drawing from your RRSP/RRIF and non-registered investments

THIS WEEK IN FLYERS

COMMENTS

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our [Community Guidelines](#) for more information and details on how to adjust your [email](#) settings.



[News](#) [FP Energy](#) [FP Finance](#) [FP Investor](#) [FP Economy](#)
[FP Work](#) [FP Comment](#) [Newsletters](#) [Business Essentials](#)
[MoneyWise Pro](#) [Refer a Friend](#) [Subscribe](#)

My Account

[Subscriber Self-Serve](#)
[ePaper](#)
[Contact Us](#)

Advertise

[Advertise With Us](#)
[Appointment Notice](#)
[Content Works](#)
[Partnerships](#)
[Resources](#)

Postmedia Network

[National Post](#)
[Regina Leader-Post](#)
[Saskatoon StarPhoenix](#)

Classified

[Remembering](#)
[Celebrating](#)
[Classifieds Marketplace](#)
[Careers](#)
[FlyerCity](#)
[Post a Classified ad](#)
[Local Directory](#)

Sales

[About Us](#)

[Driving.ca](#)
[The Province](#)
[Vancouver Sun](#)

Windsor Star
Ottawa Citizen
Winnipeg Sun
London Free Press
Canada.com
Canoe.com

Edmonton Journal
Calgary Herald
Montreal Gazette
Toronto Sun
Ottawa Sun
Calgary Sun
Edmonton Sun

National Post
NATIONAL POST >

Follow us



Give us some feedback!

365 Bloor Street East, Toronto, Ontario, M4W 3L4

© 2021 Financial Post, a division of Postmedia Network Inc. All rights reserved. Unauthorized distribution, transmission or republication strictly prohibited.

[Privacy](#) - [Updated Terms](#) [Copyright](#) [Digital Ad Registry](#)

[Sitemap](#) [Contact us](#)